An interventional study of Monoplace Hyperbaric Chamber (Class III medical device) in Endometriosis-related Pain, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Endometriosis with a site in Canada — 12 open to participants now, 13 under way, none of them phase 3. Endometriosis · Canada.
Among the 34 studies in Endometriosis with a site in Canada, this one is the 12th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 31st registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →12 of the 34 studies in Endometriosis with a site in Canada are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Canada
Ages 18–45 · Women only
Trio Fertility · Sites in Canada
Ages 18–45 · Women only · Healthy volunteers
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Andrew Zakhari · Sites in Canada
Ages 18+ · Women only
University of Ottawa · Sites in Canada
Ages 18–60 · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is close to the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 64 across the 23 interventional studies, 126 across the 11 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Sunnybrook Health Sciences Centre has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Endometriosis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05643131Hyivy Health IncHyivy Device as Non-hormonal Therapy in Endometriosis | 2026-12 |
| NCT05523284McMaster UniversityCombining Ultrasound and Biomarkers to Diagnose Superficial Endometriosis | 2026-12-30 |
| NCT07713797Trio FertilityBiomarkers for Endometriosis | 2027-01-01 |
| NCT07731776Université de SherbrookeImproving Access to Pelvic Health Physiotherapy for Endometriosis | 2027-03-29 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 34 studies in Endometriosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endometriosis, is a condition where tissue from the uterus, called endometrium, grows outside of the uterus. This effects up to 10% of women, and can lead to long-lasting, moderate to severe pelvic pain, infertility and other symptoms. This can affect a woman's quality of life (including increased risk of depression and anxiety) and is associated with increased healthcare costs.
Current treatments are often limited by serious side effects, and many women resort to surgery. Surgery is also associated with complications and there are long wait times for procedures, sometimes over 3 years. This means that many women continue to suffer from symptoms while they wait for surgery. Therefore, new effective treatments for endometriosis pain are needed.
New research suggests that inflammation and stress caused by lack of oxygen in the affected areas may cause endometriosis. Hyperbaric Oxygen Therapy (HBOT), where patients are placed in a small chamber with higher than normal levels of oxygen, suppresses inflammation and promotes tissue healing. Because inflammation is central to this condition, HBOT has emerged as a potential treatment.
In this study, the investigators will test if HBOT, in addition to the standard treatments, is more effective at treating endometriosis pain than the standard treatments alone.
Endometriosis is caused when endometrial-like tissue is found outside of the uterus. It predominantly affects women of reproductive age, with an estimated prevalence of 10% worldwide. Chronic pain related to endometriosis is one of the primary manifestations that lead individuals to seek treatment, with many women reporting moderate to severe pain that can have serious consequences for mental health and quality of life.
Current therapeutic approaches for endometriosis include hormonal therapies (e.g. oral contraceptive pills, progestins, and Gonadotropin-Releasing Hormone agonists/antagonists). While these treatments may provide temporary symptom relief, they are often associated with serious side effects and preclude conception during treatment. The efficacy of other medical interventions remains controversial, therefore surgical procedures are often indicated. However, surgery also has associated risks, has long wait times (between 6 months and 3 years), and a considerable percentage of patients experience recurrence of pain following surgical resection.
Pathologically, endometriosis is characterized by angiogenesis, inflammation, and a chronic hypoxic state at the cellular level. Because of this, Hyperbaric Oxygen Therapy (HBOT), which suppresses inflammation and promotes tissue healing, offers promise as a novel therapeutic modality. This is supported by murine models, which demonstrate the ability of HBOT to reduce inflammation and inflammatory cytokines in the context of endometriosis in animals. However, there have not been any human studies investigating the use of HBOT for treatment of endometriosis and related pain.
This study aims to explore HBOT as a treatment for endometriosis related pelvic pain. Specifically, the investigators will test if HBOT, in addition to the standard treatments (e.g. hormonal and non-hormonal medical options), is more effective at treating endometriosis pain than the standard treatments alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard multi-modal therapy
Standard multi-modal therapy + 40 HBOT treatments (2 ATM for 90 mins daily, 5 days a week)
Device: Monoplace Hyperbaric Chamber (Class III medical device)
Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.
Change in pain symptoms on the NRS
Assessed on the numeric rating scale between 0 to 10, with 10 indicating the worst possible pain
Time frame: At baseline, weekly for the first 8 weeks after enrollment, then at 3/4/5/6 month follow ups
Change in pain frequency
The change in pain frequency will be assessed on a 5-point Likert scale, where 1 is "never" and 5 is "always."
Time frame: At baseline, weekly for the first 8 weeks after enrollment, then at 3/4/5/6 month follow ups
Change in opioid consumption
Collected as a categorical variable ("Are you taking 1) more, 2) same or 3) less compared to start of treatment?")
Time frame: At baseline, weekly for the first 8 weeks after enrollment, then at 3/4/5/6 months
Participant Quality of Life on the EHP-30
The Endometriosis Health Profile-30 is a validated, high-sensitivity, 30-item endometriosis-specific assessment tool for capturing the impact of endometriosis on patient's lives.
Time frame: At baseline, and every month for 6 months
Participant Quality of Life on the SF-36
The Quality of Life Short Form Survey-36 is a widely used tool to assess an individual's overall health-related quality of life.
Time frame: At baseline, and every month for 6 months
Adherence to HBOT protocol
How many patients complete protocol (minimum 4 treatments per week with \>35 treatments)
Time frame: At 8 weeks (or last session)
Satisfaction assessed by a Patient Satisfaction Questionnaire
Subjective questionnaire completion at end of treatment inquiring about HBOT experience, barriers to and promoters of treatment
Time frame: At 8 weeks (or last session) and 6 months following enrollment
Cost of study completion
Cost of study completion on a per patient basis including research support, healthcare resource costs, and patient-related personal costs (transport, time from work)
Time frame: Throughout study completion, an average of 6 months
Plan to share: Yes — De-identified participant-level data will be made available upon reasonable request to study PI following publication of full trial results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available following publication of the full trial results.
Access criteria: Data and supporting information will be made available following reasonable request directly to study PI.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.
Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 32 months is above that.
Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sunnybrook Health Sciences Centre →